Boston Pharma Plays Catch Up To Akero, 89bio In MASH

 
• By Joseph Haas
  
NASH liver
Boston Pharma is trying to catch up in the FGF21 analog class in MASH • Source: Shutterstock

More from Strategy

More from Therapy Areas